FDA, CMS, and Beyond: Reimbursement Pathways Shaping the U.S. Liquid Biopsy Landscape
The global liquid biopsy for early cancer detection and monitoring market, valued at USD 2.18 billion in 2024, is anticipated to expand at a CAGR of 11.62% from 2025 to 2034, with growth increasingly driven by segment-wise performance across applications, technologies, and end-user settings. Unlike traditional tissue biopsies, liquid biopsy offers a minimally invasive alternative for detecting circulating tumor DNA (ctDNA), circulating tumor cells (CTCs), and exosomes, enabling real-time monitoring of tumor dynamics, treatment response, and resistance mechanisms. The oncology application segment dominates the market, with non-small cell lung cancer (NSCLC) accounting for the largest share due to the well-established role of EGFR and other actionable mutations in guiding targeted therapy. Application-specific growth is also evident in colorectal, breast, and prostate cancers, where liquid biopsy is being integrated into treatment pathways for therapy selection and recurrence monitoring.
